Cabaletta Bio to Participate in Upcoming Investor Conferences
Cabaletta Bio, Inc. (NASDAQ: CABA), a clinical-stage biotechnology company focused on developing curative targeted cell therapies for patients with autoimmune diseases, is set to engage in several high-profile investor conferences. These events will take place in September and provide opportunities for stakeholders to learn more about the company's mission and innovations.
Conference Details
The following are the scheduled investor conferences where Cabaletta Bio will be present:
Morgan Stanley 22nd Annual Global Healthcare Conference
Cabaletta will participate in a fireside chat on Wednesday during the conference, providing an overview of their recent developments and strategic directions.
2024 Wells Fargo Healthcare Conference
On Thursday, company representatives will discuss their innovative approaches in a fireside chat, sharing insights into their research and the therapeutic potential of their pipeline.
H.C. Wainwright 26th Annual Global Investment Conference
Another important session will take place on Wednesday, where Cabaletta will highlight its clinical advancements and projections for the future.
2024 Cantor Fitzgerald Global Healthcare Conference
The final engagement scheduled for September will be a fireside chat on Tuesday, where Cabaletta will delve into its ongoing projects and their significance in the biotech field.
Webcast Availability
Investors and interested parties can access a live webcast of each presentation via the News and Events section of Cabaletta Bio’s website. Additionally, replays of these presentations will be accessible for 30 days following the events, allowing broader audience engagement.
About Cabaletta Bio
Cabaletta Bio is at the forefront of developing engineered T cell therapies aimed at delivering potentially curative treatments for autoimmune diseases. Their proprietary CABA™ platform includes two main strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody receptor T cells).
The flagship product under the CARTA strategy is CABA-201, which is currently undergoing evaluation in several clinical studies, including the RESET™ clinical trials targeting conditions such as myositis, systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. Furthermore, the CAART strategy encompasses candidates like DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis.
Cabaletta Bio is committed to advancing its innovative therapies, aiming to provide long-lasting responses for patients with a wide spectrum of autoimmune disorders. Their headquarters, along with state-of-the-art laboratories, are located in Philadelphia.
Contacts
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
Frequently Asked Questions
What is the main focus of Cabaletta Bio?
Cabaletta Bio is dedicated to developing targeted cell therapies that aim to provide curative solutions for patients with autoimmune diseases.
Which investor conferences will Cabaletta Bio attend?
The company will participate in the Morgan Stanley Global Healthcare Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Cantor Fitzgerald Global Healthcare Conference.
How can one view the webcasts of the presentations?
Live webcasts of the presentations will be available on Cabaletta Bio’s website under the News and Events section, and replays will be accessible for 30 days post-event.
What are the key strategies within Cabaletta Bio's CABA™ platform?
The CABA™ platform includes CARTA for chimeric antigen receptor T cells and CAART for chimeric autoantibody receptor T cells, targeting various autoimmune conditions.
Where is Cabaletta Bio headquartered?
Cabaletta Bio is headquartered in Philadelphia, PA, where it operates its laboratories and main office.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Coiled Tubing Market to Reach $6.5 Billion Driven by Innovation
- NewtekOne, Inc. CEO Barry Sloane to Attend Key Conference
- AUGA group, AB Investor Conference Webinar Details
- Loupe Offers Exciting Rewards for Topps Chrome Basketball
- DCHFA Relaunches ReMIT Program to Assist Seniors
- RealManage Achieves 2024 Great Place to Work Certification
- Maternal Nutrition Products Market Set to Reach $38.66 Billion
- Spark Biomedical's Advancements in Opioid Withdrawal Therapy
- Security Robots Market Set for Growth to USD 29.65 Billion
- Banle Group Boosts Global Port Network to 60+ Ports